X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
U.S. Food and Drug Administration has accepted an investigational new drug (IND) application for a T-cell receptor (TCR) based T-Cell Therapy in oncology.
Lead Product(s): TCR based T-Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Genentech
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 09, 2023
Details:
The collaboration will cover existing and future programs to aid in the development and commercialization of investigational medicines for hematologic malignancies including, TAK-007, a CD19 chimeric antigen receptor-directed cord blood derived natural killer cell therapy.
Lead Product(s): TAK-007,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: TAK-007
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Takeda Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 12, 2023
Details:
Tecartus/(KTE-X19 (brexucabtagene autoleucel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is approved for the treatment of relapsed/refractory mantle cell lymphoma (MCL).
Lead Product(s): Brexucabtagene Autoleucel,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Tecartus
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
In the multinational phase 3 ENSEMBLE trial, participants given Johnson & Johnson’s vaccine experienced similar efficacy against the B.1.351 variant.
Lead Product(s): Ad26.COV2.S
Therapeutic Area: Infections and Infectious Diseases Product Name: JNJ-78436735
Highest Development Status: ApprovedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 09, 2021
Details:
The companies will combine expertise to discover and develop fully human neutralizing antibodies targeting SARS-CoV-2 to potentially prevent or treat COVID-19.
Lead Product(s): Human neutralizing antibodies
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 02, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
